Lipooxygenase inhibition in osteoarthritis: a potential symptomatic and disease modifying effect?
Paris-Descartes University, Medicine Faculty; UPRES-EA 4058; AP-HP, Cochin Hospital, Rheumatology B Department, Paris, France
Arthritis Research & Therapy 2008, 10:116 doi:10.1186/ar2490
See related research by Raychaudhuri et al., http://arthritis-research.com/content/10/4/R85Published: 19 September 2008
5-Loxin® is a compound extracted from an ancient herb that might be considered as a potent lipooxygenase inhibitor. The results observed in a preliminary trial suggest a highly intriguing clinically relevant symptomatic effect contrasting with a poor bioavailability of this compound. Moreover, in this trial, a statistically significant decrease in matrix metalloproteinase enzyme serum level suggests that, in addition to the observed symptomatic effect, such a compound might have a disease modifying effect in osteoarthritis. Further studies are required both to confirm the symptomatic efficacy and acceptable safety profile and to evaluate the potential chondromodulating effect of this compound.